MedTrace Logo

Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study

NCT02691351 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-09-09

No results posted yet for this study

Summary

The better understanding of non-Hodgkin T-cell lymphoma is essential for establishing effective treatment strategy for non-Hodgkin T-cell lymphoma. Therefore, the data about conical features and treatment outcomes of each subtype should be accumulated to establish treatment strategy. However, the majority of previous data for non-Hodgkin T-cell lymphoma was from small case series of single institute. Furthermore, as novel drugs were developed for the treatment of relapsed or refractory T-cell lymphoma, the date from patients who were treated with those novel drugs are especially required because their outcomes may reflect the outcomes of currently available treatments. Thus, a multinational, multicenter prospective registry study is needed to provide information useful for establishing treatment strategies for T-cell lymphoma.

Conditions

  • Non-Hodgkin T-cell Lymphoma

Interventions

OTHER

Prospective Registry

Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment 1. Regimen 2. Response Evaluation 3. SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Won seog Kim, PhD · Samsung Medical Center

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2020-07-31
Completion
2020-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02691351 on ClinicalTrials.gov